Innovative Cellular Therapeutics Holdings, Ltd.

Innovative Cellular Therapeutics, Inc.

Dongqi Chen

Chengfei Pu

Xiaogang Shen

Zhiyuan Cao

Lei Xiao

Wei Ding

Wensheng Wang

Le Tian

Beibei Jia

The present disclosure relates to compositions and methods of treating a subject having digestive tract cancer, the method comprising: administering an effective amount of a composition to the subject, the composition comprising a first population of cells comprising a first CAR binding a first antigen, and a second population of cells comprising a second CAR binding GCC, wherein the first antigen comprises a cell surface molecule of a white blood cell (WBC).

Anti-GCC antibody and CAR thereof for treating digestive system cancer

Embodiments relate to a modified cell engineered to comprise a modified TCR-CD3 complex, wherein the CD3γ, ζ-chain, CD3ε, and/or CD3δ chains of the modified TCR-CD3 complex are linked to one or more co-stimulatory signaling domains.

Modified TCR and uses thereof

Embodiments relate to a modified cell comprising a polynucleotide encoding a dominant negative form of Death receptor 5 (DR5). In embodiments, the modified cell further comprises a chimeric antigen receptor (CAR) and/or a modified TCR.

Modified cell with enhanced functionality and cellular therapy thereof

Growing community of inventors

Shanghai, China

Dongqi Chen